Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2009 1
2011 3
2012 3
2014 2
2015 22
2016 1
2017 2
2018 2
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Lessons from the Meningitis Vaccine Project.
LaForce FM, Djingarey M, Viviani S, Preziosi MP. LaForce FM, et al. Viral Immunol. 2018 Mar;31(2):109-113. doi: 10.1089/vim.2017.0120. Epub 2017 Nov 8. Viral Immunol. 2018. PMID: 29116892 Review.
From 2001 to 2017 the Meningitis Vaccine Project (MVP), a Gates Foundation funded partnership between PATH and the World Health Organization (WHO), successfully developed, tested, licensed, and introduced an affordable new Group A meningococcal conjugate vacc …
From 2001 to 2017 the Meningitis Vaccine Project (MVP), a Gates Foundation funded partnership between PATH and the Worl …
The Evolution of the Meningitis Vaccine Project.
Tiffay K, Jodar L, Kieny MP, Socquet M, LaForce FM. Tiffay K, et al. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S396-403. doi: 10.1093/cid/civ594. Clin Infect Dis. 2015. PMID: 26553666 Free PMC article. Review.
BACKGROUND: In 2001, the Meningitis Vaccine Project (MVP) was tasked to develop, test, license, and introduce a group A meningococcal (MenA) conjugate vaccine for sub-Saharan Africa. ...
BACKGROUND: In 2001, the Meningitis Vaccine Project (MVP) was tasked to develop, test, license, and introduce a group A …
From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project.
Aguado MT, Jodar L, Granoff D, Rabinovich R, Ceccarini C, Perkin GW. Aguado MT, et al. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S391-5. doi: 10.1093/cid/civ593. Clin Infect Dis. 2015. PMID: 26553665 Free PMC article. Review.
CONCLUSIONS: In June 2001, BMGF awarded a grant of US$70 million to create the Meningitis Vaccine Project (MVP) as a partnership between PATH and WHO, with the specific goal of developing an affordable MenA conjugate vaccine to eliminate MenA meningitis epide …
CONCLUSIONS: In June 2001, BMGF awarded a grant of US$70 million to create the Meningitis Vaccine Project (MVP) as a pa …
The Meningitis Vaccine Project.
LaForce FM, Konde K, Viviani S, Préziosi MP. LaForce FM, et al. Vaccine. 2007 Sep 3;25 Suppl 1:A97-100. doi: 10.1016/j.vaccine.2007.04.049. Epub 2007 May 7. Vaccine. 2007. PMID: 17521780
Conversely, polysaccharide conjugate vaccines are effective in infants and have consistently shown an important effect on decreasing carriage, two characteristics that facilitate disease control. In 2001 the Meningitis Vaccine Project (MVP) was created as a p …
Conversely, polysaccharide conjugate vaccines are effective in infants and have consistently shown an important effect on decreasing carriag …
Technical Development of a New Meningococcal Conjugate Vaccine.
Frasch CE, Kapre SV, Lee CH, Préaud JM. Frasch CE, et al. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S404-9. doi: 10.1093/cid/civ595. Clin Infect Dis. 2015. PMID: 26553667 Free PMC article. Review.
This vaccine was developed by scientists working with the Meningitis Vaccine Project, a partnership between PATH and the World Health Organization. ...
This vaccine was developed by scientists working with the Meningitis Vaccine Project, a partnership between PATH and th …
Conducting vaccine clinical trials in sub-Saharan Africa: operational challenges and lessons learned from the Meningitis Vaccine Project.
Marchetti E, Mazarin-Diop V, Chaumont J, Martellet L, Makadi MF, Viviani S, Kulkarni PS, Preziosi MP. Marchetti E, et al. Vaccine. 2012 Nov 6;30(48):6859-63. doi: 10.1016/j.vaccine.2012.09.008. Epub 2012 Sep 16. Vaccine. 2012. PMID: 22989686
Group A Neisseria meningitidis epidemics have been an important and unresolved public health problem in sub-Saharan Africa for over a century. The Meningitis Vaccine Project (MVP) was established in 2001 with the goal of developing, testing, licensing, and in …
Group A Neisseria meningitidis epidemics have been an important and unresolved public health problem in sub-Saharan Africa for over a centur …
Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India.
Kulkarni PS, Socquet M, Jadhav SS, Kapre SV, LaForce FM, Poonawalla CS. Kulkarni PS, et al. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S483-8. doi: 10.1093/cid/civ500. Clin Infect Dis. 2015. PMID: 26553678 Free PMC article. Review.
BACKGROUND: In 2002, the Meningitis Vaccine Project (MVP) chose the Serum Institute of India, Ltd (SIIL), as its manufacturing partner to establish a product development partnership (PDP) with the Meningitis Vaccine Project (MVP). ...
BACKGROUND: In 2002, the Meningitis Vaccine Project (MVP) chose the Serum Institute of India, Ltd (SIIL), as its manufa …
37 results